Intensity Therapeutics (NASDAQ:INTS) is a biotech firm deeply engaged in the development of immunotherapy treatments aimed at a variety of cancers. The company's unique approach involves directly injecting its drug candidates into solid tumors to stimulate an immune response that targets cancer cells throughout the body. Among its notable projects is INT230-6, designed to improve the effectiveness of existing cancer therapies and reduce their side effects. Intensity Therapeutics is keen on transforming cancer treatment by fostering durable responses in advanced and hard-to-treat cancers, demonstrating its commitment to changing the landscape of cancer care through innovation and research.